Abstract:Objectives: To evaluate the effectiveness of repetitive transcranial magnetic stimulation (rTMS) started with citalopram in first-episode young major depressive patients.Methods: In a 2-week double-blind study with a 2-week extended antidepressant phase, 60 first-episode young major depressive patients were randomly assigned to citalopram in combination with 2 weeks of either active or sham rTMS treatment. During the following 2 weeks, the patients continued only the citalopram treatment. The 17-item Hamilton depression rating scale (HAMD-17) and Montgomery-Asberg depression rating scale (MADRS) were used to assess the severity of depression. Moreover, the Wisconsin Card Sorting Test (WCST), Trail-Making Test (TMT), and Stroop Color-Word Test (SCWT) were used to assess executive function.Results: (1) There was a significantly greater number of early improvers (a reduction of HAMD-17 score >= 20% within the first 2 weeks) observed in the active rTMS group compared to the sham group (57% vs. 29%, chi(2)=4.667, p=0.031). (2) There was no significant difference observed in responder rates (46% vs. 36%, chi(2)=0.295, p=0.586) or in remission rates (39% vs. 29%, chi(2)=0.319, p=0.572) between the two groups at 4 weeks. (3) There was a significant difference seen in both HAMD-17 and MADRS scores between the two groups at 2 and 4 weeks. The active rTMS group showed a significantly faster score reduction compared to the sham group at 2 weeks (HAMD-17, t=13.444, p=0.001; MADRS, t=30.123, p=0.000), which was maintained at 4 weeks on both scales (HAMD-17, t=46.915, p=0.000; MADRS, t=39.996, p=0.000). (4) The patients did not deteriorate in executive performance, and even improved in categories on WCST and completed TMT faster in the active group.Conclusions: rTMS accelerated the rapidity of the antidepressant response in first-episode young depressive patients. Our results call for future rTMS studies with larger sample sizes, high intensity of stimuli, and longer duration to draw more definitive conclusions.

Mirtazapine and Fluoxetine in the Treatment of Cardiovascular Neurosis with Depression

A comparative study of treatment of depression:Mirtazapine vs.fluoxepine

Consensus of mirtazapine in treatment of depression

Efficacy and safety of olanzapine combined with fluoxetine in treatment of depression

Randomized,multicenter,double blind comparative trial of reboxetine in the treatment of depression with or without anxiety

Control study of mirtazapine and fluoxetine in therapy of depression

Efficacy and safety of venlafaxine hydrochloride combined with tandospirone citrate for patients with vascular depression accompanied by somatic symptoms: An open‐labeled randomized control trial

[Repetitive Transcranial Magnetic Stimulation Combined with Antidepressant Medication in Treatment of First-Episode Patients with Major Depression].

A study of antidepressant augmentation with mirtazapine in outpatients with major depression

The efficacy and safety of trazodone plus fluoxetine in the treatment of male depression patients

Efficacy of fluoxetine combined with psychological intervention for treatment of depressive patients with insomnia

A Preliminary Study of Different Treatment Strategies for Anxious Depression.

Study of Bupropion Hydrochloride Tablet and Fluoxetine in Treatment of Depression Multicenter Clinical Trial

Randomized Double-Blind Control Study of Olanzapine Augmented with Fluoxetine for Schizophrenia with Depression Symptom

Effectiveness of mirtazapine as add-on to paroxetine v. paroxetine or mirtazapine monotherapy in patients with major depressive disorder with early non-response to paroxetine: a two-phase, multicentre, randomized, double-blind clinical trial

Repetitive Transcranial Magnetic Stimulation In Combination With Citalopram In Young Patients With First-Episode Major Depressive Disorder: A Double-Blind, Randomized, Sham-Controlled Trial

Fluoxetine Treatment for Major Depression Decreases the Plasma Levels of Cytokines

A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression

Sertraline with desvenlafaxine and sertraline with mirtazapine as treatment initiation in MDD patients with moderate to severe depression and effect on inflammatory markers

Venlafaxine in treating 62 patients with depression: a multicenter open trial

Treatment with Bupropion Sustained Release Tablet in Patients with Depression:A Randomized,double-Blind,multi-center Clinical Trial